ReproCELL, a venture company in the iPS cell business originating from the University of Tokyo and Kyoto University, has acquired U.K.-based Reinnervate, a spin-out company from Durham University, a center of excellence in cell biology research, and BioServe Biotechnologies, based in Maryland, to accelerate its iPS cell business.
ReproCELL, Reinnervate and BioServe already serve the same types of customers, including large pharmaceutical companies, biotechnology companies, major universities and medical institutions in Europe and the U.S., respectively. The local sales and distribution experience provided by Reinnervate and BioServe will help grow ReproCELL’s market share in Europe and North America. ReproCELL’s local presence in Japan and extensive distribution networks in Asia will help to accelerate sales of Reinnervate and BioServe products in Asia.
Through the combination of Reinnervate’s innovative 3D cell culture technologies and ReproCELL’s iPS cell technologies, the next generation of iPS cell products with better functionality and usability for customers will be developed and launched globally.
Through the acquisition of BioServe, ReproCELL now will have access to large variety of patient derived cells in disease areas such as Alzheimer's, Parkinsons and cardiovascular disorders. This will accelerate the development and commercialization of diverse patient-derived iPS cell products where there is a rapidly growing market need.
Financial terms have not been disclosed.